Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A.

A L DunnS P AhujaEric S Mullins
Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2018)
In patients who switched from a standard half-life FVIII to Adynovate prophylaxis in routine clinical practice, bleeding control was generally improved or maintained, with a lower infusion frequency and factor consumption in most patients.